Welcome to visit Zhongnan Medical Journal Press Series journal website!
Zhongnan Medical Journal Press Series of Journals Center for Evidence-Based and Translational Medicine of Wuhan University

The title
  • The title
  • The keywords
  • The author
Submit中文版

HomeArticlesVol 32,2022 No.3Detail

Clinical pathway interpretation of transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia

Published on Jun. 25, 2022Total Views: 3009 timesTotal Downloads: 1066 timesDownloadMobile

Author: Si-Yu YAN 1 Xing HUANG 1, 2 Zheng CHEN 3 Lu YANG 4 Zhao-Hui JIA 5 Mou PENG 6 Xuan-Yi REN 7 Jing XIONG 8 Xiao-Dong LI 9 Xiao-Feng XU 10 Zhong-Yi SUN 11 Yong-Bo WANG 1 Xu-Hui LI 1 Wan-Li HU 2 Ting WANG 2 Ying-Hui JIN 1 Hao ZI 1, 2 Tong-Zu LIU 2 Xian-Tao ZENG 1, 2 Da-Lin HE 12 Xing-Huan WANG 2 Urological Association of Chinese Research Hospital Association Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care Project Group for Minimally Invasive Plasmakinetic Surgery System Development and Industrialization of the National Key Research and De-velopment Program

Affiliation: 1. Center for Evidence-Based and Translational Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 2. Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China 3. Department of Urology, The First Af-filiated Hospital of Jinan University, Guangzhou 510630, China 4. Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu 610041, China 5. Department of Urology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang 471003, Henan Province, China 6. Department of Urology, The Second Xiangya Hospital of Central South University, Changsha 410011, China 7. Department of Urology, Kaifeng Central Hospital, Kaifeng 475001, Henan Province, China 8. Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang 330006, China 9. Department of Urology, Huaihe Hospital of Henan University, Kaifeng 475000, Henan Province, China 10. Department of Urology, Xianyang Central Hospital, Xianyang 712000, Shannxi Province, China 11. Department of Urology, Shenzhen University General Hospital, Shenzhen 518055, China 12. Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China

Keywords: Clinical pathway Benign prostatic hyperplasia Lower urinary tract symptoms Tran-surethral plasmakinetic resection Plasma bipolar resection Evidence-based medicine

DOI: 10.12173/j.issn.1004-5511.202205003

Reference: Yan SY, Huang X, Chen Z, Yang L, Jia ZH, Peng M, Ren XY, Xiong J, Li XD, Xu XF, Sun ZY, Wang YB, Li XH, Hu WL, Wang T, Jin YH, Zi H, Liu TZ, Zeng XT, He DL, Wang XH, Urological Association of Chinese Research Hospital Association, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care, Project Group for Minimally Invasive Plasmakinetic Surgery System Development and Industrialization of the National Key Research and Development Program. Clinical pathway interpretation of transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia[J]. Yixue Xinzhi Zazhi, 2022, 32(3): 214-222. DOI: 10.12173/j.issn.1004-5511.202205003.[Article in Chinese]

  • Abstract
  • Full-text
  • References
Abstract

Benign prostatic hyperplasia is the most common benign disease that causes urination dysfunction in middle-aged and elderly men, and is also the main cause of lower urinary tract symptoms. Transurethral plasmakinetic resection of prostate has been widely used in clinical practice for its good efficacy and safety. In order to further standardize the clinical application of this surgery, the National Health Commission published the initial Clinical Pathway Interpretation of Transurethral Plasmakinetic Resection of Prostate for Benign Prostatic Hyperplasia in 2019. In view of the limited content of this clinical pathway, using it as a blueprint, we have interpreted it and applied the ideas and methods of evidence-based medicine, aiming to provide a more detailed evidence supplement to help medical staff and managers better understand, grasp and correctly use this clinical pathway.

Full-text
Please download the PDF version to read the full text: download
References

1.中国研究型医院学会泌尿外科学专业委员会， 中国医疗保健国际交流促进会泌尿健康促进分会,  中国医疗保健国际交流促进会循证医学分会, 等. 中国良性前列腺增生症经尿道等离子双极电切术治疗指南(2018标准版)[J].中华医学杂志, 2018, 98(20): 1549-1560. [Urology Professional Committee of Chinese Research Hospital Association, Urinary Health Promotion  Chapter of China Interna-tional Exchange and Promotive Association for Medical and Health Care, Evidence-Based Medicine Chapter of China International Exchange and Promotive Association for Medical and Health Care, et al. Guidelines for transurethral plasmakinetic resection of benign pros-tatic hyperplasia in China (2018 Standard Edition)[J]. National Medical Journal of China, 2018, 98(20): 1549-1560.] DOI: 10.37601cma.j.issn.0376-2491.2018.20.005.

2.EAU guideline: management of non-neurogenic male LUTS[EB/OL]. (2020-10-03) [2022-04-28]. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/.

3.黄健. 中国泌尿外科和男科疾病诊断治疗指南(2019版)[M].北京: 科学出版社, 2020. [Huang J. Guidelines for diagnosis and treatment of uroogy and andrology diseases in China (2019 Edition)[M]. Beijing: China Science Publishing & Media Ltd, 2020.]

4.Lee SWH, Chan EMC, Lai YK. The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis[J]. Sci Rep, 2017, 7(1): 7984. DOI: 10.1038/s41598-017-06628-8.

5.Zhang W, Zhang X, Li H, et al. Prevalence of lower urinary tract symptoms suggestive of be-nign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retire-ment Longitudinal Study[J]. BMJ open, 2019, 9(6): e022792. DOI: 10.1136/bmjopen-2018-022792.

6.Zhu C, Wang DQ, Zi H, et al. Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019[J]. Mil Med Res, 2021, 8(1): 64. DOI: 10.1186/s40779-021-00359-8.

7.王行环. 经尿道前列腺等离子双极电切术[J]. 医学新知, 2004, 14(1): 8-9. [Wang XH. Transurethral plasmakinetic resectic: treatment benign prostatic hyperplasia[J]. Yixue Xinzhi Zazhi, 2004, 14(1): 8-9.] DOI: 10.3969/j.issn.1004-5511.2004.01.004.

8.王永博, 阎思宇, 黄兴, 等. 经尿道前列腺等离子双极与单极电切术治疗良性前列腺增生的有效性与安全性的系统评价和Meta分析[J]. 医学新知, 2021, 31(2): 115-131. [Wang YB, Yan SY, Huang X, et al. Efficacy and safety of transurethral plasmakinetic resection of prostate versus transurethral resection for benign prostatic hyperplasia:a systematic review and meta-analysis[J]. Yixue Xinzhi Zazhi, 2021, 31(2): 115-131.] DOI: 10.12173/j.issn.1004-5511.2021.02.04.

9.李柄辉, 唐诗迪, 王永博, 等. 经尿道前列腺等离子双极电切术并发症类型及其发生率的系统评价和Meta分析[J]. 医学新知, 2021, 31(2): 88-99. [Li BH, Tang SD, Wang YB, et al. Complications of transurethral plasmakinetic resection of prostate: a systematic review and meta-analysis[J]. Yixue Xinzhi Zazhi, 2021, 31(2): 88-99.] DOI: 10.12173/j.issn.1004-5511.2021.02.02.

10.曾宪涛, 蔡广研, 陈香美, 等. 制定/修订《临床路径释义》的基本方法与程序[J]. 中华医学杂志, 2017, 97(40): 3140-3142. [Zeng XT, Cai GY, Chen XM, et al. The methods and procedures of formu-lating and revising the interpretation of clinical pathway[J]. National Medical Journal of Chi-na, 2017, 97(40): 3140-3142.] DOI: 10.19450/j.cnki.jcrh.2020.02.014.

11.国家卫生健康委办公厅关于印发有关病种临床路径（2019年版）的通知 [EB/OL]. (2020-01-02) [2022-04-28]. http://www.nhc.gov.cn/yzygj/s7659/202001/b3c9e097b0c1471a969d7a63be471759.shtml.

12.张潘, 冯佳佳, 张瑜, 等. 我国公立医院临床路径开展及管理情况分析[J]. 中国医院管理, 2019, 39(2): 41-43. [Zhang P, Feng JJ, Zhang Y, et al. Analysis of implementation and management situa-tion of clinical pathways in public hospitals in China[J]. Chinese Hospital Management, 2019, 39(2): 41-43.] DOI: CNKI:SUN: YYGL.0.2019-02-022.

13.方朕. 临床路径管理模式在医院管理中的应用现状分析[J].中国医药导报, 2017, 14(10): 166-169. [Fang Z. The application status analysis of clinical pathway management mode in hospital management[J]. China Medical Herald, 2017, 14(10): 166-169.] DOI: CNKI:SUN: YYCY.0.2017-10-042.

14.曾宪涛, 冯佳佳, 蔡广研 , 等. 制定/修订《临床路径释义》的基本方法与程序 (2020年更新版)[J]. 中国研究型医院, 2020, 7(2): 65-68. [Zeng XT, Feng JJ, Cai GY, et al. The methods and procedures of formulating and revising the interpretation of clinical pathway (2020 update)[J]. Journal of Chinese Research Hospitals, 2020, 7(2): 65-68.] DOI: 10.19450/j.cnki.jcrh.2020.02.014.

15.周利群, 王行环. 临床路径释义(泌尿外科分册)[M].北京: 中国协和医科大学出版社, 2018. [Zhou LQ, Wang XH. Interpretation of Clinical Pathway[M]. Beijing: Peking Union Medical College Press, 2018.]

16.中国研究型医院学会泌尿外科学专业委员会, 中国医疗保健国际交流促进会泌尿健康促进分会, 中国医疗保健国际交流促进会循证医学分会, 等. 中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018简化版)[J].中国循证医学杂志, 2018, 18(12): 1267-1272. [Urological Association of Chinese Research Hospital Association (CRHA-UA), Urinary Health Promotion Branch of China Medi-cal and Healthcare International Exchange Promotion Association, Uro-Health Promotive Association of China International Exchange and Promotive Association for Medical and Health Care (CPAM-UHPA). Treatment and surveillance for non-muscle-invasive bladder cancer in China: an evidence-based clinical practice guideline (2018 simplified version)[J]. Chinese Journal of Evidence-Based Medicine, 2018, 18(12): 1267-1272.] DOI: 10.7507/1672-2531.201812031.

17.Zeng XT, Jin YH, Liu TZ, et al. Clinical practice guideline for transurethral plasmakinetic re-section of prostate for benign prostatic hyperplasia (2021 Edition)[J]. Mil Med Res, 2022, 9(1): 14. DOI: 10.1186/s40779-022-00371-6.

18.孙自学, 宋春生, 邢俊平, 等. 良性前列腺增生中西医结合诊疗指南(试行版) [J]. 中华男科学杂志, 2017, 23(3): 280-285. [Sun ZX, Song CS, Xing JP, et al. Guidance on diagnosis and treatment of integrated Chinese and western medicine for benign prostatic hyperplasia (trial version)[J]. National Journal of Andrology, 2017, 23(3): 280-285.] DOI: 10.13263/j.cnki.nja.2017.03.017.

19.Management of Benign Prostatic Hyperplasia/ Lower Urinary Tract Symptoms: AUA Guide-line 2021[EB/OL]. [2022-04-28]. https://www.auanet.org/guidelines/guidelines/benign-prostatic-hyperplasia-(bph)-guideline.

20.国家卫生计生委办公厅，国家中医药管理局办公室和解放军总后勤部卫生部药品器材局. 关于印发抗菌药物临床应用指导原则（2015年版）的通知（国卫办医发〔2015〕43号附件）[EB/OL]. (2015-07-24) [2022-04-28]. http://www.gov.cn/xinwen/2015-08/27/content_2920799.htm.

Popular Papers
© 2022 - 2024 Zhongnan Medical Journal Press of Zhongnan Hospital of Wuhan University|Support: Yufu Technology
About NM | Contact us